Thalidomide for the treatment of acute myeloid leukemia

Leukemia and Lymphoma

Volumn 44, Issue 9, 2003, Pages 1489-1493

  Steins, M B ^a   Bieker, R ^a   Padro T ^a   Kessler, T ^a   Kienast, J ^a   Berdel, W E ^a   Mesters, R M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Acute myeloid leukemia; Angiogenesis; Microvessel density; Myelodysplastic syndrome; Thalidomide

Indexed keywords

AMIKACIN; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTILEUKEMIC AGENT; CEFTRIAXONE; CYTARABINE; CYTOTOXIC AGENT; HEMOGLOBIN; MITOXANTRONE; TEICOPLANIN; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTEREMIA; BLAST CELL; BONE MARROW; CANCER REGRESSION; CELL INFILTRATION; CLINICAL TRIAL; CONSTIPATION; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; HUMAN; LEUKEMIA CELL; LONG TERM CARE; MALE; MICROVASCULATURE; POLYNEUROPATHY; PRIORITY JOURNAL; RASH; THROMBOCYTE COUNT; THROMBOSIS PREVENTION;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BONE MARROW; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOVASCULARIZATION, PATHOLOGIC; PILOT PROJECTS; PROSPECTIVE STUDIES; SAFETY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0038574583     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000077043     Document Type: Article

References (36)

1. Folkman, J., Watson, K., Ingber, D. and Hanahan, D. (1989) "Induction of angiogenesis during the transition from hyperplasia to neoplasia", Nature 339, 58-61.
2. Craft, P.S. and Harris, A.L. (1994) "Clinical prognostic significance of tumour angiogenesis", Annals of Oncology 5, 305-311.
3. Pruneri, G., Bertolini, F., Soligo, D., Carboni, N., Cortelezzi, A., Ferrucci, P.F., Buffa, R., Lambertenghi-Deliliers, G. and Pezzella, F. (1999) "Angiogenesis in myelodysplastic syndromes", British Journal of Cancer 81, 1398-1401.
4. Hussong, J.W., Rodgers, G.M. and Shami, P.J. (2000) "Evidence of increased angiogenesis in patients with acute myeloid leukaemia", Blood 95, 309-313.
5. Padró, T., Ruiz, S., Bieker, R., Bürger, H., Steins, M., Kienast, J., Büchner, T., Berdel, W.E. and Mesters, R.M. (2000) "Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia", Blood 95, 2637-2644.
6. Aguayo, A., O'Brien, S., Keating, M., Manshouri, T., Barlogie, B., Koller, C., Kantarjian, H. and Albitar, M. (2000) "Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes", Blood 96, 2240-2245.
7. Padró, T., Bieker, R., Ruiz, S., Steins, M., Retzlaff, S., Bürger, H., Büchner, T., Kessler, T., Herrera, F., Kienast, J., Müller-Tidow, C., Serve, H., Berdel, W.E. and Mesters, R.M. (2002) "Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia", Leukemia 16, 1302-1310.
8. Bellamy, W.T., Richter, L., Frutiger, Y. and Grogan, T.M. (1999) "Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies", Cancer Research 59, 728-733.
9. Perez-Atayde, A.R., Sallan, S.E., Tedrow, U., Connors, S., Allred, E. and Folkman, J. (1997) "Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia", American Journal of Pathology 150, 815-821.
10. Fiedler, W., Graeven, U., Ergün, S., Verago, S., Kilic, N., Stockschläder, M. and Hossfeld, D.K. (1997) "Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia", Blood 89, 1870-1875.
11. Dias, S., Hattori, K., Zhu, Z., Heissig, B., Choy, M., Lane, W., Wu, Y., Chadburn, A., Hyjek, E., Gill, M., Hicklin, D.J., Witte, L., Moore, M.A. and Rafii, S. (2000) "Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration", The Journal of Clinical Investigation 106, 511-521.
12. Bellamy, W.T., Richter, L., Sirjani, D., Roxas, C., Glinsmann-Gibson, B., Frutiger, Y., Grogan, T.M. and List, A.F. (2001) "Vascular endothelial growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes", Blood 97, 1427-1434.
13. Aguayo, A., Estey, E., Kantarjian, H., Manshouri, T., Gidel, C., Keating, M., Giles, F., Estrov, Z., Barlogie, B. and Albitar, M. (1999) "Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia", Blood 94, 3717-3721.
14. D'Amato, R.J., Loughnan, M.S., Flynn, E. and Folkman, J. (1994) "Thalidomide is an inhibitor of angiogenesis", Proceedings of the National Academy of Sciences USA 91, 4082-4085.
15. Kenyon, B.M., Browne, F. and D'Amato, R.J. (1997) "Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization", Experimental Eye Research 64, 971-978.
16. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J. and Barlogie, B. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", The New England Journal of Medicine 341, 1565-1571.
17. Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L., Nascimben, F., duRandt, M., Kaspar, C., Goldberg, C., Loew, J., Dar, S., Gezer, S., Venugopal, P. and Zeldis, J. (2001) "Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes", Blood 98, 958-965.
18. Strupp, C., Germing, U., Aivado, M., Misgeld, E., Haas, R. and Gattermann, N. (2002) "Thalidomide for the treatment of patients with myelodysplastic syndromes", Leukemia 16, 1-6.
19. Steins, M.B., Padró, T., Bieker, R., Ruiz, S., Kropff, M., Kienast, J., Kessler, T., Büchner, T., Berdel, W.E. and Mesters, R.M. (2002) "Efficacy and safety of thalidomide in patients with acute myeloid leukemia", Blood 99, 834-839.
20. Bowcock, S.J., Rassam, S.M., Ward, S.M., Turner, J.T. and Laffan, M. (2002) "Thromboembolism in patients on thalidomide for myeloma", Hematology 7, 51-53.
21. Zangari, M., Anaissie, E., Barlogie, B., Badros, A., Desikan, R., Gopal, A.V., Morris, C., Toor, A., Siegel, E., Fink, L. and Tricot, G. (2001) "Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy", Blood 98, 1614-1615.
22. Zangari, M., Siegel, E., Barlogie, B., Anaissie, E., Saghafifar, F., Fassas, A., Morris, C., Fink, L. and Tricot, G. (2002) "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy", Blood 100, 1168-1171.
23. Löwenberg, B., Downing, J.R. and Burnett, A. (1999) "Acute myeloid leukemia", The New England Journal of Medicine 341, 1051-1062.
24. Cheson, B.D., Cassileth, P.A., Head, D.R., Schiffer, C.A., Bennett, J.M., Bloomfield, C.D., Brunning, R., Gale, R.P., Grever, M.R., Keating, M.J., Sawitsky, A., Stass, S., Weinstein, H. and Woods, W.G. (1990) "Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia", Journal of Clinical Oncology 8, 813-819.
25. Bertolini, F., Mingrone, W., Alietti, A., Ferrucci, P.F., Cocorocchio, E., Peccatori, F., Cinieri, S., Mancuso, P., Corsini, C., Burlini, A., Zucca, E. and Martinelli, G. (2001) "Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers", Annals of Oncology 12, 987-990.
26. Moreira, A.L., Friedlander, D.R., Shif, B., Kaplan, G. and Zagzag, D. (1999) "Thalidomide and thalidomide analogue inhibit endothelial cell proliferation in vitro", Journal of Neurooncology 43, 109-114.
27. Parman, T., Wiley, M.J. and Wells, P.G. (1999) "Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity", Nature Medicine 5, 582-585.
28. Jacobson, J.M., Greenspan, J.S., Spritzler, J., Ketter, N., Fahey, J.L., Jackson, J.B., Fox, L., Chernoff, M., Wu, A.W., McPhail, L.A., Vasquez, G.J. and Wohl, D.A. (1997) "Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group", The New England Journal of Medicine 336, 1487-1493.
29. Haslett, P.A., Corral, L.G., Albert, M. and Kaplan, G. (1998) "Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset", Journal of Experimental Medicine 187, 1885-1892.
30. Rovelli, A., Arrigo, C., Nesi, F., Balduzzi, A., Nicolini, B., Locasciulli, A., Vasallo, E., Miniero, R. and Uderzo, C. (1998) "The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children", Bone Marrow Transplantation 21, 577-581.
31. Hamuryudan, V., Mat, C., Saip, S., Ozyazgan, Y., Siva, A., Yurdakul, S., Zwingenberger, K. and Yazici, H. (1998) "Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: A randomized, double-blind, placebo-controlled trial", Annals of Internal Medicine 128, 443-450.
32. Geitz, H., Handt, S. and Zwingenberger, K. (1996) "Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade", Immunopharmacology 31, 213-221.
33. Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A. and Kaplan, G. (1991) "Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes", Journal of Experimental Medicine 173, 699-703.
34. Moreira, A.L., Sampaio, E.P., Zmuidzinas, A., Frindt, P., Smith, K.A. and Kaplan, G. (1993) "Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation", Journal of Experimental Medicine 177, 1675-1680.
35. Moller, D.R., Wysocka, M., Greenlee, B.M., Ma, X., Wahl, L., Flockhart, D.A., Trinchieri, G. and Karp, C.L. (1997) "Inhibition of IL-12 production by thalidomide", Journal of Immunology 159, 5157-5161.
36. Estey, E., Albitar, M., Cortes, J., Giles, F., Thomas, D., Koller, C., Beran, M. and Kantarjian, H. (2000) "Addition of thalidomide (T) to chemotherapy did not increase remission rate in poor prognosis AML/MDS", Blood 96, 323a.